These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33521512)

  • 1. Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.
    Farquhar H; Vargas-Santos AB; Pisaniello HL; Fisher M; Hill C; Gaffo AL; Stamp LK
    Rheumatol Adv Pract; 2021; 5(1):rkaa073. PubMed ID: 33521512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews.
    Kydd AS; Seth R; Buchbinder R; Falzon L; Edwards CJ; van der Heijde DM; Bombardier C
    J Rheumatol Suppl; 2014 Sep; 92():33-41. PubMed ID: 25180126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for tophi in gout.
    Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies.
    Jeong HJ; Park WY; Kim SH; Dalbeth N; Son CN
    Semin Arthritis Rheum; 2022 Oct; 56():152073. PubMed ID: 35914389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
    Kim SH; Lee SY; Kim JM; Son CN
    Korean J Intern Med; 2020 Jul; 35(4):998-1003. PubMed ID: 30959584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
    Sapankaew T; Thadanipon K; Ruenroengbun N; Chaiyakittisopon K; Ingsathit A; Numthavaj P; Chaiyakunapruk N; McKay G; Attia J; Thakkinstian A
    BMC Nephrol; 2022 Jun; 23(1):223. PubMed ID: 35739495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
    Lertnawapan R; Jatuworapruk K
    Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
    Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y
    Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
    Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
    Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
    Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
    Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.
    Pisaniello HL; Fisher MC; Farquhar H; Vargas-Santos AB; Hill CL; Stamp LK; Gaffo AL
    Arthritis Res Ther; 2021 Apr; 23(1):130. PubMed ID: 33910619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout.
    Broadwell A; Albert JA; Padnick-Silver L; LaMoreaux B
    Rheumatol Ther; 2022 Dec; 9(6):1549-1558. PubMed ID: 36136270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series.
    Albert J; Broadwell A; Padnick-Silver L; Marder B; LaMoreaux B
    Medicine (Baltimore); 2024 Mar; 103(10):e37424. PubMed ID: 38457582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
    Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
    J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.
    Liu D; Zhou B; Li Z; Zhang Z; Dai X; Ji Z; Chen H; Sun Y; Jiang L
    Clin Rheumatol; 2022 Jul; 41(7):2121-2128. PubMed ID: 35229198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.